Stella Pharma
4888.TLOWNuclear Medicine / Fusion · Weight: 1%· Data as of 2026-04-21
¥525+2.14%
6-month dailyInvestment Thesis
World ONLY producer of pharmaceutical-grade boron drug (Steboronin) for BNCT cancer therapy. Japan is 5+ years ahead of any country. Micro-cap (12B), speculative but truly unique monopoly.
Risk
Loss-making biotech. PB 9x for money-losing company. Share dilution +4.1% YoY. BNCT adoption extremely slow. Speculative call option only.
Monitoring Trigger
BNCT treatment volume growth. International regulatory approvals.
Key Metrics
null
PE
null
Fwd PE
9.04
P/B
-9.8%
ROE
-23.6%
Op Margin
29%
D/E
0%
Div Yield
N/A
FCF
¥24.4B
Mkt Cap
Peer Comparison
| Company | PE | Fwd PE | ROE | Op Margin | FCF |
|---|---|---|---|---|---|
| IHI Corporation | 23.7 | 22 | 26.8% | 8.8% | +¥68B |
| Hitachi | 28.96 | 27.58 | 13.65% | 11.1% | +¥1,390B |
| Japan Steel Works | 33.5 | 31.1 | 9.09% | 8.4% | -¥19.7B |
| Yokogawa Electric | 38.8 | 23.8 | 11.5% | 13.7% | +¥44B |
| Fuji Electric | 20.3 | 17.7 | 11.8% | 10.3% | +¥51B |
| Kanadevia | 10.97 | 11 | 5.2% | 1.9% | -¥22.6B |
| Organo Corporation | 27 | 27 | 21.7% | 20.6% | +¥19B |
| Kurita Water Industries | 22.3 | 21.8 | 6.8% | 12.4% | +¥25B |
| Sumitomo Heavy Industries | 19.3 | 18 | 5.0% | 4.8% | -¥2.3B |
| Toyo Tanso | 23.2 | 23.8 | 5.7% | 14.6% | -¥5.8B (capex phase) |
| Okano Valve | 21.6 | 8.2% | 10.1% | +¥624M | |
| Kobe Steel | 8.7 | 8.5 | 7.2% | 4.8% | N/A |
| Ebara | 30.9 | 25.4 | 15.8% | 12.1% | -¥51.5B (capex) |
| Stella Pharma | -9.8% | -23.6% | N/A | ||
| Teikoku Denki | 10.49 | 9.5 | 12% | 18% | N/A |